BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 34952583)

  • 1. p53 signaling in cancer progression and therapy.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Morrione A; Giordano A; Cenciarelli C
    Cancer Cell Int; 2021 Dec; 21(1):703. PubMed ID: 34952583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
    Huang Y; Jiao Z; Fu Y; Hou Y; Sun J; Hu F; Yu S; Gong K; Liu Y; Zhao G
    Eur J Med Chem; 2024 Feb; 265():116121. PubMed ID: 38194777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Function of the Mutant p53-R175H in Cancer.
    Chiang YT; Chien YC; Lin YH; Wu HH; Lee DF; Yu YL
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
    Saleh A; Perets R
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of p53 Signaling in Colorectal Cancer.
    Liebl MC; Hofmann TG
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33924934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting p53 pathways: mechanisms, structures, and advances in therapy.
    Wang H; Guo M; Wei H; Chen Y
    Signal Transduct Target Ther; 2023 Mar; 8(1):92. PubMed ID: 36859359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor p53 and its gain-of-function mutants in cancer.
    Liu J; Zhang C; Feng Z
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.
    Ferraiuolo M; Verduci L; Blandino G; Strano S
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent findings on the role of wild-type and mutant p53 in cancer development and therapy.
    Babamohamadi M; Babaei E; Ahmed Salih B; Babamohammadi M; Jalal Azeez H; Othman G
    Front Mol Biosci; 2022; 9():903075. PubMed ID: 36225257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 in Cancer Progression and Targeted Therapies.
    Zhu G; Pan C; Bei JX; Li B; Liang C; Xu Y; Fu X
    Front Oncol; 2020; 10():595187. PubMed ID: 33240819
    [No Abstract]   [Full Text] [Related]  

  • 13. A common gain of function of p53 cancer mutants in inducing genetic instability.
    Liu DP; Song H; Xu Y
    Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Song H; Hollstein M; Xu Y
    Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.
    Blandino G; Valenti F; Sacconi A; Di Agostino S
    Semin Cell Dev Biol; 2020 Feb; 98():105-117. PubMed ID: 31112799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complexes formed by mutant p53 and their roles in breast cancer.
    Bellazzo A; Sicari D; Valentino E; Del Sal G; Collavin L
    Breast Cancer (Dove Med Press); 2018; 10():101-112. PubMed ID: 29950894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions.
    Deppert W
    J Cell Biochem; 1996 Aug; 62(2):172-80. PubMed ID: 8844397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.
    Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M
    Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of p53 in regulation of hematopoiesis in health and disease.
    Barajas S; Cai W; Liu Y
    Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.